HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan drives anti-aging skin-care market

This article was originally published in The Rose Sheet

Executive Summary

According to market research firm Mintel, the number of anti-aging skin-care products launched in Japan from 2007 to 2009 increased 85%, compared to a 27% increase in the U.S. during the same time period. Longevity among Japanese women leads the world and its steady increase, "traditional eating habits and long history of whitening beauty are just a few of the reasons this region continues to excel in the personal-care industry," Mintel's Hinako Sugioka says in Sept. 22 release. Sales of anti-aging skin-care products in the U.S. topped $1.8 bil. in 2009, with growth attributed to increased interest in health and wellbeing among women in the U.S. The market has also shown resilience to the economic downturn, with many women unwilling to stop buying anti-aging skin-care products, Sugioka noted

You may also be interested in...



Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

UsernamePublicRestriction

Register

RS017213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel